“…We read with interest the "Assessment of intrathoracic impedance algorithm in the pediatric and adult congenital heart population" by Silva et al, 1 particularly because the authors contrast our own paper on the subject. 2 Silva et al conclude, in their Medtronic-funded study, that Optivol (Medtronic Inc., Minneapolis, MN, USA)-an intrathoracic impedance monitoring feature in cardiac devices-has considerably greater utility than found in our own analysis.…”